Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Q24236701)

1

0 references

Paresh Jobanputra

2

0 references

Juan B Cabello

4

0 references

José G Gálvez Muñoz

5

0 references

Encarnación SC Saiz Cuenca

6

0 references

Anne Fry-Smith

Cochrane Database of Systematic Reviews

7

0 references

publication date

16 February 2011

0 references

published in

0 references

cites work

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Targeting cytokines in autoimmunity: new approaches, new promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

The influence of the hormonal system on pediatric rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Reciprocal interactions between the neuroendocrine and immune systems during inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Cytokine inhibitors in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Biologic therapies in clinical development for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

New therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Treatment of rheumatoid arthritis by TNF-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

CDP-870 (certolizumab) in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Current methods for the generation of human antibodies for the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Targeting tumour necrosis factor in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Strategies for targeting tumour necrosis factor in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Anti-cytokines and cytokines in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

The use of TNF-alpha blocking agents in rheumatoid arthritis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Pathogenesis of rheumatoid arthritis: targeting cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Genetic susceptibility to rheumatoid arthritis: an emerging picture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Infliximab for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Etanercept for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Evidence that cytokines play a role in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

The prevalence of rheumatoid arthritis in the general population of Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Work disability in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Early environmental factors and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Room for improvement? A survey of the methods used in systematic reviews of adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

An assessment of clinically useful measures of the consequences of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Rituximab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Abatacept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Explaining heterogeneity in meta-analysis: a comparison of methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Optimal CINAHL search strategies for identifying therapy studies and review articles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Anti-TNF Biological Agents in Rheumatoid Arthritis and Other Inflammatory Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Analysing Data and Undertaking Meta-Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

Tocilizumab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

Estimating rates of change in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

First-in-class biologic to enter rheumatoid arthritis fray

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

1 reference

7 January 2021

Rheumatoid arthritis market

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

CDP 571: anti-TNF monoclonal antibody, BAY 103356, BAY W 3356, Humicade

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

[Focus on biological agents in rheumatoid arthritis: newer treatments and therapeutic strategies]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007649.PUB2

7 January 2021